Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 1003 in Bipolar I Disorder (Acute Manic or Mixed Episodes)
NCT00374920Phase 2Completed
- Sponsor
- Memory Pharmaceuticals
- Start
- Sep 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar I disorder comparing MEM 1003 Arm with Placebo Arm (2 arms). Primary endpoint: Response rate at Day 21. Started Sep 2006; status: completed.
02
Drugs
MEM 1003
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00374920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00374920.